Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 6 studies | 46% ± 17% | |
| astrocyte | 6 studies | 35% ± 19% | |
| oligodendrocyte | 6 studies | 37% ± 16% | |
| GABAergic neuron | 4 studies | 43% ± 13% | |
| oligodendrocyte precursor cell | 4 studies | 41% ± 18% | |
| interneuron | 4 studies | 53% ± 29% | |
| rod bipolar cell | 3 studies | 38% ± 19% | |
| microglial cell | 3 studies | 32% ± 12% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 6 studies | 44% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 68% | 313.71 | 311 / 459 | 4% | 0.07 | 40 / 1118 |
| blood vessel | 71% | 323.88 | 945 / 1335 | 0% | 0 | 0 / 0 |
| esophagus | 62% | 268.04 | 890 / 1445 | 5% | 0.10 | 10 / 183 |
| pancreas | 65% | 338.04 | 214 / 328 | 1% | 0.03 | 1 / 178 |
| intestine | 65% | 307.21 | 629 / 966 | 0% | 0.00 | 2 / 527 |
| lung | 63% | 294.25 | 365 / 578 | 2% | 0.05 | 26 / 1155 |
| adipose | 65% | 276.11 | 783 / 1204 | 0% | 0 | 0 / 0 |
| bladder | 62% | 250.24 | 13 / 21 | 1% | 0.06 | 6 / 504 |
| uterus | 62% | 376.80 | 105 / 170 | 1% | 0.01 | 3 / 459 |
| prostate | 61% | 174.18 | 149 / 245 | 1% | 0.03 | 6 / 502 |
| skin | 59% | 266.88 | 1076 / 1809 | 2% | 0.03 | 9 / 472 |
| ovary | 60% | 376.19 | 108 / 180 | 0% | 0 | 0 / 430 |
| thymus | 58% | 194.76 | 380 / 653 | 1% | 0.02 | 9 / 605 |
| stomach | 57% | 188.00 | 204 / 359 | 1% | 0.07 | 4 / 286 |
| brain | 52% | 209.70 | 1382 / 2642 | 5% | 0.07 | 33 / 705 |
| heart | 56% | 153.16 | 486 / 861 | 0% | 0 | 0 / 0 |
| muscle | 53% | 124.15 | 423 / 803 | 0% | 0 | 0 / 0 |
| adrenal gland | 50% | 166.11 | 128 / 258 | 1% | 0.02 | 3 / 230 |
| spleen | 44% | 97.29 | 105 / 241 | 0% | 0 | 0 / 0 |
| kidney | 36% | 70.01 | 32 / 89 | 5% | 0.18 | 41 / 901 |
| peripheral blood | 17% | 78.83 | 162 / 929 | 0% | 0 | 0 / 0 |
| liver | 13% | 16.34 | 29 / 226 | 0% | 0.00 | 1 / 406 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.03 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0046904 | Molecular function | calcium oxalate binding |
| Gene name | CCDC144A |
| Protein name | Coiled-coil domain containing 144A Coiled-coil domain-containing protein 144A CCDC144A protein (Coiled-coil domain containing 144A) CCDC144A protein |
| Synonyms | KIAA0565 |
| Description | FUNCTION: May play a role in preventing the formation of kidney stones through inhibition of calcium oxalate monohydrate (COM) crystallization, attenuating COM-induced apoptotic injury to renal epithelial cells . May exhibit antilithiatic (preventing the formation of kidney stones) activity through crystal binding, hindering the crystal attachment to renal epithelial cells, a pre-requisite to initiate inflammatory response . . |
| Accessions | ENST00000340621.9 C9JAY6 ENST00000399273.5 A6NJB5 A6NG92 B7ZM27 ENST00000360524.12 [A2RUR9-1] C9JT67 ENST00000420937.5 ENST00000448331.7 A2RUR9 ENST00000697416.1 ENST00000360495.9 A0A8V8TL21 |
